Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.

Lymphoid enhancer-binding factor 1 (LEF1) is a neutrophilic granulopoiesis regulator whose absence is critical in congenital neutropenia. We have shown LEF1 downregulation in the CD34(+) cells of the majority of myelodysplastic syndromes (MDS) patients. LEF1 was the most significant differentially e...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Pellagatti, A, Marafioti, T, Paterson, J, Malcovati, L, Della Porta, MG, Jädersten, M, Pushkaran, B, George, T, Arber, D, Killick, S, Giagounidis, A, Hellström-Lindberg, E, Cazzola, M, Wainscoat, J, Boultwood, J
Natura:	Journal article
Lingua:	English
Pubblicazione:	2009

Documenti analoghi

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
di: Pellagatti, A, et al.
Pubblicazione: (2009)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
di: Pellagatti, A, et al.
Pubblicazione: (2010)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
di: Pellagatti, A, et al.
Pubblicazione: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
di: Pellagatti, A, et al.
Pubblicazione: (2011)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
di: Pellagatti, A, et al.
Pubblicazione: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
di: Pellagatti, A, et al.
Pubblicazione: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
di: Pellagatti, A, et al.
Pubblicazione: (2010)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
di: Pellagatti, A, et al.
Pubblicazione: (2008)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes
di: Pellagatti, A, et al.
Pubblicazione: (2007)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
di: Boultwood, J, et al.
Pubblicazione: (2009)

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
di: Pellagatti, A, et al.
Pubblicazione: (2013)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: Involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
di: Pellagatti, A, et al.
Pubblicazione: (2006)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
di: Pellagatti, A, et al.
Pubblicazione: (2009)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
di: Pellagatti, A, et al.
Pubblicazione: (2008)

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
di: Boultwood, J, et al.
Pubblicazione: (2010)

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts
di: Boultwood, J, et al.
Pubblicazione: (2008)

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
di: Boultwood, J, et al.
Pubblicazione: (2007)

COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
di: Pellagatti, A, et al.
Pubblicazione: (2014)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
di: Pellagatti, A, et al.
Pubblicazione: (2005)

Genome-wide analysis of copy number change and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density SNP arrays
di: Wang, L, et al.
Pubblicazione: (2007)

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
di: Pellagatti, A, et al.
Pubblicazione: (2006)

Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
di: Wang, L, et al.
Pubblicazione: (2008)

Identification of aberrant splicing events in myelodysplastic syndrome patients with splicing factor gene mutations
di: Pellagatti, A, et al.
Pubblicazione: (2017)

Gene expression profiling in the myelodysplastic syndromes.
di: Pellagatti, A, et al.
Pubblicazione: (2005)

Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays
di: Li Wang, et al.
Pubblicazione: (2008-07-01)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
di: Jadersten, M, et al.
Pubblicazione: (2005)

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
di: Pellagati, A, et al.
Pubblicazione: (2008)

High-resolution genomic profiling of myelodysplasia (MDS) by microarray comparative genomic hybridization (CGH).
di: Esoof, N, et al.
Pubblicazione: (2006)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
di: Pellagatti, A, et al.
Pubblicazione: (2004)

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
di: Pellagatti, A, et al.
Pubblicazione: (2006)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
di: Malcovati, L, et al.
Pubblicazione: (2011)

Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome.
di: Pellagatti, A, et al.
Pubblicazione: (2010)

Clonality in the myelodysplastic syndromes.
di: Boultwood, J, et al.
Pubblicazione: (2001)

Myelodysplastic/myeloproliferative disorders
di: Luca Malcovati, et al.
Pubblicazione: (2008-01-01)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
di: Scharenberg, C, et al.
Pubblicazione: (2011)

Molecular pathogenesis of the myelodysplastic syndromes
di: Boultwood, J, et al.
Pubblicazione: (1999)

Myelodysplastic syndromes with bone marrow fibrosis
di: Matteo Giovanni Della Porta, et al.
Pubblicazione: (2011-02-01)

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
di: Fernandez-Mercado, M, et al.
Pubblicazione: (2013)

Myelodysplastic syndromes
di: Eva Hellström Lindberg
Pubblicazione: (2018-06-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
di: Pellagatti, A, et al.
Pubblicazione: (2003)